Skip to main content

Table 1 Characteristics of included studies

From: Effect of vitamin D supplementation on cardiac-metabolic risk factors in elderly: a systematic review and meta-analysis of clinical trials

Author, year Country Study population Study design Sex Sample size Dose of
Vitamin D
(IU)
Mean age (SD) Intervention duration Baseline Vitamin D Level (nmol/L)
Mean (SD)
outcomes
Witham 2010 UK DM RCT M/F I1: 19
I2: 20
P: 22
Two single doses
I1: 100,000 IU
I2: 200,000 IU
I1:65.3 (11.1)
I2:63.3 (9.6)
P: 66.7 ( 9.7)
I1:48 (21)
I2:41(14)
P: 45 ( 17)
HOMA-IR
HbA1c
TC
Naharci 2012 Turkey IFG Non-RCT M/F I: 28
P: 23
Deficient:
300,000 IU/week
Insufficient:
880 IU/day
Normal:
400 IU/day
I: 75.1 (7.3)
P: 76.1( 5.4)
5 months I: 47.5 (24.2)
P: 55.8 (37.4)
FBS
HOMA-IR
Insulin
TC, TG, LDL, HDL
LDL/HDL ratio
BMI
Witham 2012 UK Patient with a history of stroke RCT M/F I: 30
P: 28
A single dose 100,000 IU I: 66.2 (13)
P: 67.7 ( 6.9)
- I: 38.7 (17.6)
P: 38.7 (17.8)
TC
Wood 2012 UK Postmenopausal women RCT F I1:102
I2:101
P: 102
I1: 400 IU/day
I2: 1000 IU/day
I1: 63.5(1.9)
I2: 64.1 (2.3)
P: 63.9 (2.3)
12 months I1:32.7(12.9)
I2:32.4(13.8)
P: 36.1 (17.1)
FBS
HOMA-IR
Insulin
TC, TG, LDL, HDL
Kim 2014 Korea DM RCT M/F I: 11
P: 13
1200 IU /day I: 73.2 (2.0)
P: 70 (1.3)
12 weeks I: 26.1(4.4)
P: 29.1 (6.9)
FBS
HOMA-IR
Insulin
TC, TG, LDL, HDL
BMI
El-Hajj Fuleihan 2017 Qatar Overweight RCT M/F High dose(I):
110
Low dose(P):
112
High dose(I):
3750 IU/day
Low dose(P):
600 IU/day
T: 71 (4) 12 months I: 52.1(17.4)
P: 49.9(20.4)
FBS
HOMA-IR
HbA1c, Insulin
TC, TG, LDL, HDL
Walter Verrusio, 2017 Italy Healthy Before and After M/F 200 4000 IU/day T: 65.9 (9.8) 6 months
Prusik 2018 Poland Healthy RCT M/F I: 48
P: 31
4000 IU/day T: 68.4 ( 5.0) 12 weeks I: 45.1(22.7)
P: 60.4(30.2)
TC, TG, LDL, HDL
LDL/HDL ratio
BMI
El Hajj 2019 Lebanon Healthy RCT M/F I: 60
P: 55
10,000 IU/week I: 73.05 (1.95)
P:73.56 (2.14)
6 months I: 25.2 (6.9)
P:26.2 (2.14)
BMI
WC
Wenclewska 2019 Poland Healthy & DM RCT M/F I: 48
P: 44
2000 IU / day I: 63.43(1.5)
P: 69.78 (2.1)
3 months I: 18.2 (3.2)
P:18.0(2.1)
FBS
HOMA-IR
HbA1c
TC, TG, LDL, HDL
LDL/HDL ratio
BMI
Hoseini 2020 Iran NAFLD RCT M/F I: 10
P: 10
50,000 IU/week I: 61.3 (1.4)
P: 62 (1.8)
8 weeks I: 22.9 (4.3)
P: 24.0 (4.3)
FBS
HOMA-IR
Insulin
TC, TG, LDL, HDL
El Hajj 2020 Lebanon DM RCT M/F I: 45
P: 43
30,000 IU/week I: 66.9 (4.1)
P: 65.7 (4.5)
6 months I:14.8 (4.5)
P:15.0 (4.2)
FBS
HOMA-IR
HbA1c
TC, TG, LDL, HDL
BMI, WC
  1. RCT Randomized controlled trial, I Intervention, P Placebo, SD standard deviation, M male, F female, DM Diabetes mellitus, IFG Impaired fasting glucose, NAFLD Non- alcoholic fatty liver disease, IU International unit, HOMA-IR Homeostatic Model Assessment of Insulin Resistance, HbA1c Hemoglobin A1c, FBS Fasting blood sugar, TC Total cholesterol, TG Triglyceride, HDL high-density lipoprotein, LDL low-density lipoprotein, BMI Body mass index, WC Waist circumference